Colchicine administration for percutaneous coronary intervention: A meta-analysis of randomized controlled trials

The efficacy of colchicine administration in patients undergoing percutaneous coronary intervention (PCI) remains controversial. We conduct a systematic review and meta-analysis to explore the influence of colchicine administration versus placebo on treatment efficacy for PCI.

We search PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through June 2020 for randomized controlled trials (RCTs) assessing the effect of colchicine administration versus placebo in patients with PCI. This meta-analysis is performed using the random-effect model.

Five RCTs involving 5526 patients are included in the meta-analysis. Overall, compared with control group for myocardial infarction patients undergoing PCI, colchicine intervention can significantly reduce major adverse cardiovascular events (OR = 0.78; 95% CI = 0.62 to 0.97; P = 0.02), but reveals no obvious impact on mortality (OR = 0.89; 95% CI = 0.60 to 1.32; P = 0.57), myocardial infarction (OR = 0.88; 95% CI = 0.67 to 1.17; P = 0.39), serious adverse events (OR = 0.71; 95% CI = 0.31 to 1.61; P = 0.41), or restenosis (OR = 1.02; 95% CI = 0.63 to 1.64; P = 0.95).

Colchicine treatment may be effective to reduce major adverse cardiovascular events in patients undergoing PCI.